Merck Research Laboratories

Latest stories

12d
WCSH 6 Portland
Lung Cancer Trial Stopped After Jimmy Carter Drug Shrinks Tumorsdata with the medical community and with regulatory authorities around the worl
Lung Cancer Trial Stopped After Jimmy Carter Drug Shrinks Tumors
WCSH 6 Portland / Posted 12 days ago
data with the medical community and with regulatory authorities around the world," said Dr. Roger Perlmutter, president, of Merck Research Laboratories. Independent committees look at the details of the patients and how well they are doing in drug... Read more
7 related stories
12d
WLBZ Bangor
Lung Cancer Trial Stopped After Jimmy Carter Drug Shrinks Tumorsdata with the medical community and with regulatory authorities around the worl
Lung Cancer Trial Stopped After Jimmy Carter Drug Shrinks Tumors
WLBZ Bangor / Posted 12 days ago
data with the medical community and with regulatory authorities around the world," said Dr. Roger Perlmutter, president, of Merck Research Laboratories. Independent committees look at the details of the patients and how well they are doing in drug... Read more
7 related stories
13d
Philly.com
Innovative Merck lung cancer therapy bests chemo in trialthe therapeutic paradigm in first-line treatment of non-small cell lung cancer,
Innovative Merck lung cancer therapy bests chemo in trial
Philly.com / Posted 13 days ago
the therapeutic paradigm in first-line treatment of non-small cell lung cancer," said Roger M. Perlmutter, president of Merck Research Laboratories. "We look forward to sharing these data with the medical community and with regulatory... Read more
3 related stories
13d
NBC News
Lung Cancer Trial Stopped When Jimmy Carter Drug Shrinks Tumorsdata with the medical community and with regulatory authorities around the worl
Lung Cancer Trial Stopped When Jimmy Carter Drug Shrinks Tumors
NBC News / Posted 13 days ago
data with the medical community and with regulatory authorities around the world," said Dr. Roger Perlmutter, president, of Merck Research Laboratories. "I suspect the findings were significant enough that this will be a practice-changing finding,"... Read more
7 related stories
13d
FOX Business
Merck's Stock Surges On Positive Results From Cancer-treatment Studychange the therapeutic paradigm in first-line treatment of non-small-cell lung
Merck's Stock Surges On Positive Results From Cancer-treatment Study
FOX Business / Posted 13 days ago
change the therapeutic paradigm in first-line treatment of non-small-cell lung cancer," said Roger Perlmutter, president of Merck Research Laboratories. The stock has climbed 6.2% year to date through Wednesday, while the Dow Jones Industrial... Read more
3 related stories
13d
FOX Business
Merck's Stock Surges On Positive Results From Cancer-treatment Studychange the therapeutic paradigm in first-line treatment of non-small-cell lung
Merck's Stock Surges On Positive Results From Cancer-treatment Study
FOX Business / Posted 13 days ago
change the therapeutic paradigm in first-line treatment of non-small-cell lung cancer," said Roger Perlmutter, president of Merck Research Laboratories. The stock has climbed 6.2% year to date through Wednesday, while the Dow Jones Industrial... Read more
3 related stories
13d
Market Watch
Merck's stock surges on positive results from cancer-treatment studychange the therapeutic paradigm in first-line treatment of non-small-cell lung
Merck's stock surges on positive results from cancer-treatment study
Market Watch / Posted 13 days ago
change the therapeutic paradigm in first-line treatment of non-small-cell lung cancer," said Roger Perlmutter, president of Merck Research Laboratories. The stock has climbed 6.2% year to date through Wednesday, while the Dow Jones Industrial... Read more
3 related stories
19d
NJ Biz
Merck paying $500M for California biotech firmcandidates selectively targeting the P2X3 receptor, an exciting area of researc
Merck paying $500M for California biotech firm
NJ Biz / Posted 19 days ago
candidates selectively targeting the P2X3 receptor, an exciting area of research,” Dr. Roger M. Perlmutter, president of Merck Research Laboratories, said in a prepared statement. “We look forward to advancing these innovative molecules for... Read more
8 related stories
20d
Business Wire
Merck to Acquire Afferent Pharmaceuticalscandidates selectively targeting the P2X3 receptor, an exciting area of researc
Merck to Acquire Afferent Pharmaceuticals
Business Wire / Posted 20 days ago
candidates selectively targeting the P2X3 receptor, an exciting area of research,” said Dr. Roger M. Perlmutter, president, Merck Research Laboratories. “We look forward to advancing these innovative molecules for patients with conditions like... Read more
8 related stories
24d
Business Wire
New Data from Phase 2 Study Evaluating KEYTRUDA® (pembrolizumab) for the Treatment of Cancers Deficient in DNA Mismatch Repair Show Durable Responses Across a Range of Cancersdeficient tumors,” said Dr. Roger Dansey, senior vice president and therapeutic
New Data from Phase 2 Study Evaluating KEYTRUDA® (pembrolizumab) for the Treatment of Cancers Deficient in DNA Mismatch Repair Show Durable Responses Across a Range of Cancers
Business Wire / Posted 24 days ago
deficient tumors,” said Dr. Roger Dansey, senior vice president and therapeutic area head, oncology late-stage development, Merck Research Laboratories. “Characterization of biomarkers with the potential to predict clinical outcomes for patients... Read more
19 related stories
24d
Business Wire
New Data for KEYTRUDA® (pembrolizumab) in Combination with Talimogene Laherparepvec, Dabrafenib Plus Trametinib, or Low-Dose Ipilimumab in Advanced Melanoma Presented at 2016 ASCO Annual Meetingtolerability,” said Dr. Roger Dansey, senior vice president and therapeutic are
New Data for KEYTRUDA® (pembrolizumab) in Combination with Talimogene Laherparepvec, Dabrafenib Plus Trametinib, or Low-Dose Ipilimumab in Advanced Melanoma Presented at 2016 ASCO Annual Meeting
Business Wire / Posted 24 days ago
tolerability,” said Dr. Roger Dansey, senior vice president and therapeutic area head, oncology late-stage development, Merck Research Laboratories. “These encouraging early data point to the potential for KEYTRUDA to become an important... Read more
19 related stories
25d
Business Wire
New Data Evaluating KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy for First-Line Treatment of Non-Small Cell Lung Cancer Demonstrate Response Rates Ranging from 48 to 71 Percentcell lung cancer,” said Dr. Roger Dansey, senior vice president and therapeutic
New Data Evaluating KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy for First-Line Treatment of Non-Small Cell Lung Cancer Demonstrate Response Rates Ranging from 48 to 71 Percent
Business Wire / Posted 25 days ago
cell lung cancer,” said Dr. Roger Dansey, senior vice president and therapeutic area head, oncology late-stage development, Merck Research Laboratories. “This study has helped us to identify chemotherapy options for combination with KEYTRUDA... Read more
6 related stories
25d
Business Wire
New KEYTRUDA® (pembrolizumab) Data from KEYNOTE-010 and KEYNOTE-001 in Advanced Non-Small Cell Lung Cancer, Including Survival Data, To Be Presented at 2016 ASCO Annual Meetingpatients,” said Dr. Roger Dansey, senior vice president and therapeutic area he
New KEYTRUDA® (pembrolizumab) Data from KEYNOTE-010 and KEYNOTE-001 in Advanced Non-Small Cell Lung Cancer, Including Survival Data, To Be Presented at 2016 ASCO Annual Meeting
Business Wire / Posted 25 days ago
patients,” said Dr. Roger Dansey, senior vice president and therapeutic area head, oncology late-stage development, Merck Research Laboratories. “The KEYNOTE-010 data show that there is a correlation between increased levels of PD-L1... Read more
19 related stories
28d
Business Wire
Merck to Hold Investor Briefing at 2016 ASCO Annual Meeting(NYSE:MRK), known as MSD outside the United States and Canada, announced today
Merck to Hold Investor Briefing at 2016 ASCO Annual Meeting
Business Wire / Posted 28 days ago
(NYSE:MRK), known as MSD outside the United States and Canada, announced today that Dr. Roger M. Perlmutter, president, Merck Research Laboratories, will present an overview of the company’s oncology program at the 52nd Annual Meeting of the... Read more

People in this news